Search research articles
Contact Us
Filters
Showing results (11-20 of 195) with videos related to
Page
of 20
Sort By:
Gene Therapy
|
March 8, 2022
Friend or Foe(tal): challenges in development of a large animal model for pre-clinical fetal gene therapy
Richard S Finkel, Christian L Lorson
Journal of Neuromuscular Diseases
|
October 25, 2025
Real-world evidence on nusinersen treatment of persons with SMA: a focused review
Susan E Matesanz, Richard S Finkel
The New England Journal of Medicine
|
July 16, 2004
Blue cohosh and perinatal stroke
Richard S Finkel, Karen M Zarlengo
Neurology
|
November 26, 2008
Linking SMN to SMA: an assay for the rescuer
Carsten G Bönnemann, Richard S Finkel
Neuromuscular Disorders : NMD
|
August 1, 2017
Spinal muscular atrophy: A changing phenotype beyond the clinical trials
Eduardo F Tizzano, Richard S Finkel
The New England Journal of Medicine
|
July 2, 2025
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. Reply
Richard S Finkel, Lutz Mueller, Heidemarie Kletzl
Nature Reviews. Neurology
|
June 17, 2026
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions
Eugenio Mercuri, Richard S Finkel, Francesco Muntoni
Neuromuscular Disorders : NMD
|
April 11, 2017
218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016
Richard S Finkel, Thomas Sejersen, Eugenio Mercuri, et al.
Muscle & Nerve
|
May 31, 2017
Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study
Kathie M Bishop, Jacqueline Montes, Richard S Finkel
Frontiers in Neurology
|
August 28, 2020
Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
Richard S Finkel, Ulrike Schara-Schmidt, Tim Hagenacker
Page
of 20
Search research articles
Search
Showing results (11-20 of 195) with videos related to
Sort By:
Page
of 20
Gene Therapy
|
March 8, 2022
Friend or Foe(tal): challenges in development of a large animal model for pre-clinical fetal gene therapy
Richard S Finkel, Christian L Lorson
Journal of Neuromuscular Diseases
|
October 25, 2025
Real-world evidence on nusinersen treatment of persons with SMA: a focused review
Susan E Matesanz, Richard S Finkel
The New England Journal of Medicine
|
July 16, 2004
Blue cohosh and perinatal stroke
Richard S Finkel, Karen M Zarlengo
Neurology
|
November 26, 2008
Linking SMN to SMA: an assay for the rescuer
Carsten G Bönnemann, Richard S Finkel
Neuromuscular Disorders : NMD
|
August 1, 2017
Spinal muscular atrophy: A changing phenotype beyond the clinical trials
Eduardo F Tizzano, Richard S Finkel
The New England Journal of Medicine
|
July 2, 2025
Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. Reply
Richard S Finkel, Lutz Mueller, Heidemarie Kletzl
Nature Reviews. Neurology
|
June 17, 2026
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions
Eugenio Mercuri, Richard S Finkel, Francesco Muntoni
Neuromuscular Disorders : NMD
|
April 11, 2017
218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016
Richard S Finkel, Thomas Sejersen, Eugenio Mercuri, et al.
Muscle & Nerve
|
May 31, 2017
Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study
Kathie M Bishop, Jacqueline Montes, Richard S Finkel
Frontiers in Neurology
|
August 28, 2020
Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
Richard S Finkel, Ulrike Schara-Schmidt, Tim Hagenacker
Page
of 20